邱清旗

基本資料

姓名：
邱清旗

電子信箱：

ccchei@mail.cgu.edu.tw
ccchei178@gmail.com

連絡電話/傳真：
TEL: (03)2118800 ext:3708

服務機構 / 服務單位 / 現任職稱 (可多項填寫)：
長庚大學

長庚大學醫學生物技術暨檢驗學系 

助理教授

機構地址：
桃園市龜山區文化一路259號

個人網站：

https://ccchei178.wixsite.com/my-site-1

研究領域：
神經科學、神經退化疾病、細胞分子生物學、誘導性多功能幹細胞、突變帕金森病基因嵌入小鼠、生物化學 、醫學生物技術

個人簡歷

自2009年從長庚大學生物醫學所博士班畢業後，便至林口長庚醫院服務至今。2015年擔任長庚醫院神經科學研究中心助理研究員，目前為長庚大學醫學生物技術暨檢驗學系助理教授。神經科研實驗室研究以神經退化疾病為研究主軸，以體學方法尋找神經退化疾病相關之生物標記，積極建立神經退化疾病突變基因之基因嵌入小鼠與基因剃除小鼠，探討突變基因所造成神經退化機轉。此外並從臨床神經退化病患檢體建立誘導性多功能幹細胞，進行致病機轉研究。發展神經保護藥物小分子也是神經科研實驗室長期發展目標，持續與國內外單位合作，利用神經科研所建立之細胞與動物模式進行研究。

在體學研究方面，利用帕金森病患血液檢體，尋找帕金森病之生物標記。找到發現大量Rab35蛋白質，發現可能透過α-synuclein蛋白質異常堆積與分泌，造成神經細胞死亡，並同時檢測血液中Rab35與α-synuclein量能作為預測帕金森病的生物標記。此外也在發現miR-204在帕金森病患者血液檢體中大量存在，可能透過影響DYRK1A基因，而影響細胞傳遞路徑異常，造成神經細胞死亡。

在基因嵌入小鼠研究方面，建立突變PLA2G6基因嵌入小鼠，突變PLA2G6會造成小鼠多巴胺神經細胞內粒線體功能與結構異常，造成多巴胺神經細胞死亡，此動物模式能模擬早發性帕金森病，並能用來探討早發性帕金森病之機轉研究。也從臨床帶有PLA2G6突變的帕金森病患血液檢體建立誘導性多功能幹細胞，分化成多巴胺神經，進行神經保護藥物篩選。

在小分子藥物研究方面，與史丹佛大學合作，發現Alda-1小分子，會專一性結合至ALDH2並增加其活性，保護粒線體活性與降低自由基產生，並減緩神經毒物誘導的細胞凋亡。也將Alda-1應用至肌腱病變的小鼠模式，發現Alda-1能減少發炎激素(IL-1β和TNF-α)，保護肌腱細胞，減少其細胞凋亡。

發表論文或著作等

1.         Chiu CC, Weng YH, Huang YZ, Chen RS, Liu YC, Yeh TH, Lu CS, Lin YW, Chen YJ, Hsu CC, Chiu CH, Wang YT, Chen WS, Liu SY, Wang HL. (D620N) VPS35 causes the impairment of Wnt/β-catenin signaling cascade and mitochondrial dysfunction in a PARK17 knockin mouse model. Cell Death Dis. 2020 Nov 30;11(11):1018. doi: 10.1038/s41419-020-03228-9. IF= 6.304, Ranking= 40/195; 20.51% (Cell Biology).

2.         Liu YC, Wang HL, Huang YZ, Weng YH, Chen RS, Tsai WC, Yeh TH, Lu CS, Chen YL, Lin YW, Chen YJ, Hsu CC, Chiu CH, Chiu CC* (*Corresponding author). Alda-1, an activator of ALDH2, ameliorates Achilles tendinopathy in cellular and mouse models. Biochem Pharmacol. 2020 Mar 16:113919. doi:10.1016/j.bcp.2020.113919. IF= 4.960, Ranking= 26/270; 9.815% (Pharmacology & Pharmacy).

3.         Wang HL, Lu CS, Yeh TH, Shen YM, Weng YH, Huang YZ, Chen RS, Liu YC, Cheng YC, Chang HC, Chen YL, Chen YJ, Lin YW, Hsu CC, Chiu CC* (*Corresponding author). Combined assessment of serum alpha-synuclein and Rab35 is a better biomarker for Parkinson's disease. J Clin Neurol. 2019 Oct;15(4):488-495. IF= 2.439, Ranking= 112/204; 54.90% (Clinical Neurology).

4.         Chiu CC, Yeh TH, Chen RS, Chen HC, Huang YZ, Weng YH, Cheng YC, Liu YC, Cheng AJ, Lu YC, Chen YJ, Lin YW, Hsu CC, Chen YL, Lu CS, Wang HL. Upregulated expression of microRNA-204-5p leads to the death of dopaminergic cells by targeting DYRK1A-mediated apoptotic signaling cascade. Front Cell Neurosci. 2019 Sep 13; 13:399. IF=3.921, Ranking= 91/271; 33.40% (Neuroscience).

5.         Chiu CC, Wang HL, Weng YH, Chen RS, Chen CM, Yeh TH, Lu CS, Chen YJ, Liu YC, Huang YZ and Chang KH. Generation of induced pluripotent stem cells from a young-onset Parkinson's disease patient carrying the compound heterozygous PLA2G6 p.D331Y/p.M358IfsX mutations. Stem Cell Res. 2019 Oct; 40:101552. IF= 4.489, Ranking= 27/156; 16.987% (Biotechnology & Applied microbiology).

6.         Chiu CC, Lu CS, Weng YH, Chen YL, Huang YZ, Chen RS, Cheng YC, Huang YC, Liu YC, Lai SC, Lin KJ, Lin YW, Chen YJ, Chen CL, Yeh TH, Wang HL. PARK14 (D331Y) PLA2G6 causes early-onset degeneration of substantia nigra dopaminergic neurons by inducing mitochondrial dysfunction, ER stress, mitophagy impairment and transcriptional dysregulation in a knockin mouse model. Mol Neurobiol. 2019 Jun;56(6):3835-3853. IF= 4.500, Ranking= 65/272; 23.897% (Neuroscience); 59/366; 16.12% (Neuroscience & Behavior).

7.         Yeh TH, Liu HF, Li YW, Lu CS, Shih HY, Chiu CC, Lin SJ, Huang YC, Cheng YC. C9orf72 is essential for neurodevelopment and motility mediated by Cyclin G1. Exp Neurol. 2018 Mar 6;304: 114-124. IF= 4.691, Ranking= 59/271; 21.587% (Neuroscience); 36/365 (Neuroscience & Behavior).

8.         Chiu CC, Yeh TH, Lu CS, Huang YC, Cheng YC, Huang YZ, Weng YH, Liu YC, Lai SC, Chen YL, Chen YJ, Chen CL, Chen HY, Lin YW, Wang HL. PARK14 PLA2G6 mutants are defective in preventing rotenone-induced mitochondrial dysfunction, ROS generation and activation of mitochondrial apoptotic pathway. Oncotarget. 2017 Sep 15;8(45):79046-79060. Ranking=62/321 (Oncology).

9.         Huang YC, Lin SJ, Shih HY, Chou CH, Chu HH, Chiu CC, Yuh CH, Yeh TH, Cheng YC. Epigenetic regulation of NOTCH1 and NOTCH3 by KMT2A inhibits glioma proliferation. Oncotarget. 2017 Jun 27;8(38):63110-63120. Ranking=62/321 (Oncology).

10. Chiu CC, Yeh TH, Lai SC, Huang YC, Chen YJ, Chen CL, Wang HL, Lu CS. Increased Rab35 expression is a potential biomarker and implicated in the pathogenesis of Parkinson's disease. Oncotarget. 2016 Aug 23;7(34):54215-54227. Ranking=62/321 (Oncology).

11. Cheng YC, Huang YC, Yeh TH, Shih HY, Lin CY, Lin SJ, Chiu CC, Huang CW, Jiang YJ. Deltex1 is inhibited by the Notch-Hairy/E(Spl) signaling pathway and induces neuronal and glial differentiation. Neural Dev. 2015 Dec 30;10:28. IF= 2.630; 40.244% Ranking= 17/41 (Developmental Biology); 167/271, 61.439% (Neuroscience). 

12. Chou AH, Chen YL, Chiu CC, Yuan SJ, Weng YH, Yeh TH, Lin YL, Fang JM, Wang HL. T1-11 and JMF1907 ameliorate polyglutamine-expanded ataxin-3-induced neurodegeneration, transcriptional dysregulation and ataxic symptom in the SCA3 transgenic mouse. Neuropharmacology. 2015 Aug 6;99:308-317. IF= 4.431, 43/271; 15.87% (Pharmacology & Pharmacy). 68/272; 25% (Neuroscience)

13. Chiu CC, Yeh TH, Lai SC, Wu-Chou YH, Chen CH, Mochly-Rosen D, Huang YC, Chen YJ, Chen CL, Chang YM, Wang HL, Lu CS. Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism. Exp Neurol. 2015 Jan; 263:244-53. IF= 4.691, Ranking=60/267, 21.59% (Neuroscience); 36/365 (Neuroscience & Behavior).

14. Huang YC, Shih HY, Lin SJ, Chiu CC, Ma TL, Yeh TH, Cheng YC. The epigenetic factor Kmt2a/Mll1 regulates neural progenitor proliferation and neuronal and glial differentiation. Dev Neurobiol. 2015 May;75(5):452-62. IF= 3.935, Ranking= 8/41 (Developmental Biology); 89/271, 18.293% (Neuroscience).

15. Chiu CC, Lee LY, Li YC, Chen YJ, Lu YC, Li YL, Wang HM, Chang JT, Cheng AJ. Grp78 as a therapeutic target for refractory head-neck cancer with CD24(-)CD44(+) stemness phenotype. Cancer Gene Ther. 2013 Nov;20(11):606-15. IF= 4.534, Ranking= 25/156; 15.705% (Biotechnology & Applied microbiology).

16. Chen YJ, Lee LY, Chao YK, Chang JT, Lu YC, Li HF, Chiu CC, Li YC, Li YL, Chiou JF, Cheng AJ. DSG3 facilitates cancer cell growth and invasion through the DSG3-plakoglobin-TCF/LEF-Myc/cyclin D1/MMP signaling pathway. PLoS One. 2013 May 30;8(5): e64088. IF= 2.740, Ranking= 27/71; 37.324% (Multidisciplinary Sciences).

17. Chiu CC, Lin CY, Lee LY, Chen YJ, Lu YC, Wang HM, Liao CT, Chang JT, Cheng AJ. Molecular chaperones as a common set of proteins that regulate the invasion phenotype of head and neck cancer. Clin Cancer Res. 2011 Jul 15; 17(14):4629-41. IF= 10.107, Ranking= 17/244; 6.762% (Oncology).

18. Lin TY, Chang JT, Wang HM, Chan SH, Chiu CC, Lin CY, Fan KH, Liao CT, Chen IH, Liu TZ, Li HF, Cheng AJ. Proteomics of the radioresistant phenotype in head-and-neck cancer: Gp96 as a novel prediction marker and sensitizing target for radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):246-56. IF= 5.859, Ranking= 10/133; 7.143 (Radiology, nuclear medicine and imaging).

19. Chang JT, Kuo TF, Chen YJ, Chiu CC, Lu YC, Li HF, Shen CR, Cheng AJ. Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers. Cancer Gene Ther. 2010 Dec;17(12):827-36. IF= 4.534, Ranking= 25/156; 15.705% (Biotechnology & Applied microbiology).

20. Lin CY, Chen WH, Liao CT, Chen IH, Chiu CC, Wang HM, Yen TC, Lee LY, Chang JT, Cheng AJ. Positive association of glucose-regulated protein 78 during oral cancer progression and the prognostic value in oral precancerous lesions. Head Neck. 2010 Aug; 32(8):1028-39. IF= 2.538, Ranking= 9/42; 20.238% (Otorhinolaryngology).

21. Kang CJ, Chen YJ, Liao CT, Wang HM, Chang JT, Lin CY, Lee LY, Wang TH, Yen TC, Shen CR, Chen IH, Chiu CC, Cheng AJ. Transcriptome profiling and network pathway analysis of genes associated with invasive phenotype in oral cancer. Cancer Lett. 2009 Nov 1;284 (2):131-40. Epub 2009 May 19. IF= 7.360, Ranking= 30/244, 12.09 % (Oncology).

22. Chiu CC, Lin CY, Lee LY, Chen YJ, Kuo TF, Chang JT, Liao CT, Wang HM, Yen TC, Shen CR, Liao SK, Cheng AJ. Glucose-regulated protein 78 regulates multiple malignant phenotypes in head and neck cancer and may serve as a molecular target of therapeutic intervention. Mol Cancer Ther. 2008 Sep; 7(9):2788-97. IF= 5.615, Ranking= 50/244, 20.287% (Oncology).

23. Chen YJ, Chang JT, Liao CT, Wang HM, Yen TC, Chiu CC, Lu YC, Li HF, Cheng AJ. Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci. 2008 Aug;99(8):1507-14. IF= 4.966, Ranking= 65/244, 26.434% (Oncology).

24. Chen YJ, Chang JT, Lee L, Wang HM, Liao CT, Chiu CC, Chen PJ, Cheng AJ. DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. Oncogene. 2007 Jan 18;26(3):467-76. IF= 7.971, Ranking= 26/244, 10.451% (Oncology).

專利

早發型帕金森病(D331Y) PLA2G6突變基因嵌入模式與藥物篩選平台和方法, 台灣, 邱清旗, 林口長庚醫院, 神經科學研究中心, 邱清旗、葉篤學、王鴻利, I695891, 2020.6.11~2039.1.2

專一性抑制葡萄糖調節蛋白78(Grp78)  表現之RNA干擾(RNAi)序列、抑制藥劑及抑制方法, 台灣, 鄭恩加, 長庚大學, 醫學檢驗暨生物技術學系, 鄭恩加、張東杰、邱清旗, I371285, 2012.9.1~2028.01.10

完整個人履歷(學歷、經歷、殊榮、學會或專業認證…等)

學歷

2005.09~2009.12 長庚大學生物醫學所生化暨分生組博士班

2003.09~2005.06 長庚大學醫學檢驗暨生物技術所碩士班

1999.09~2003.06 中山醫學大學醫學檢驗暨生物技術學系

經歷

2021.08~迄今　專任助理教授－長庚大學醫學生物技術暨檢驗學系

2020.12~2021.07　副研究員－林口長庚醫院神經科學研究中心

2015.02~2020.12 助理研究員－林口長庚醫院神經科學研究中心

2016.06~迄今　兼任助理教授－長庚科技大學

2013.02~2015.02 博士後研究員－林口長庚醫院神經科學研究中心

2011.09~2012.12 博士後研究員－林口長庚醫院癌症分子診斷中心

獲獎

1.        2020年12月長庚醫院優秀論文

2.        2020年9月科技部吳大猷先生紀念獎

3.        2020年5月長庚醫院優秀論文

4.        2019年6月長庚醫院優秀論文

5.        2018年美國科學年會-Merck Travel Award

6.        2018年5月長庚醫院優秀論文

7.        2016年8月長庚醫院優秀論文

8.        長庚大學生技所論文壁報比賽第二名

9.        2002年國科會大專生專題研究計畫

執照

1.   醫學檢驗師執照

2.   Emergency medical technician (EMT-1), Taiwan